

# NCI's Clinical Trials Cooperative Groups National Meetings Report

## Summer 2010

### In This Issue

American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), Gastrointestinal Cancers Symposium, Genitourinary Cancers Symposium, Society of Gynecologic Oncologists, International Conference on Cancer Nursing, Society for Clinical Trials, and Others

### Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Leukemia, Myelodysplasia, and Transplantation](#)
- [Lung Cancer](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

### NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD and DCP Activities](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

### Research Highlights in this Issue:

**GOG-0218:** Bevacizumab is the first anti-angiogenic agent to demonstrate benefit in a population of newly diagnosed, previously untreated epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer patients following abdominal surgery for staging and maximal effort at tumor debulking; stage III (macroscopic residual disease) or stage IV disease. Front-line treatment of these patients with standard chemotherapy plus concurrent and maintenance bevacizumab was found to prolong progression-free survival.

**E2303:** The addition of cetuximab to standard adjuvant chemotherapy (mFOLFOX6) in wild-type KRAS patients with stage III colon cancer did not improve survival.



## Cooperative Group Abstracts

### Breast Cancer

#### ACOSOG

Buzdar A, Suman V, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig GW, Ellis MJ, Ewer M, Hunt K: Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer. *J Clin Oncol* 2010; 28(15s): Abst. 594.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/594](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/594)

Protocol(s): ACOSOG-Z1041

Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K: ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. *J Clin Oncol* 2010; 28(18s): Abst. CRA504.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/CRA504](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA504)

Other Participant(s): OTHER

Protocol(s): ACOSOG-Z0010

Ellis MJ, Babiera G, Unzeitig GW, Marcom PK, Guenther JM, Deshryver FK, Allred DC, Suman V, Hunt K, Olson JA: ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. *J Clin Oncol* 2010; 28(18s): Abst. LBA513.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA513](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA513)

Protocol(s): ACOSOG-Z1031

Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow M, Blumencranz PW, Leitch AM, Saha S, Hunt K, Ballman KV: ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. *J Clin Oncol* 2010; 28(18s): Abst. CRA506.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/CRA506](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA506)

Other Participant(s): NCCTG

Protocol(s): ACOSOG-Z0011

Hunt K, Le-Petross HT, Suman V, Haffty BG, Leitch AM, Ollila D, Byrd DR, Buchholz TA, Symmans WF, Boughey JC: A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071. *J Clin Oncol* 2010; 28(15s): Abst. TPS118.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS118](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS118)

Protocol(s): ACOSOG-Z1071

## CALGB

Hughes KS, Schnaper LA, Cirincione C, Berry DA, McCormick B, Muss HB, Shank B, Hudis C, Winer EP, Smith BL: Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. *J Clin Oncol* 2010; 28(15s): Abst. 507.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/507](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/507)

Other Participant(s): ECOG, RTOG

Protocol(s): CALGB-9343

Sikov WM, Perou CM, Golshan M, Collyar D, Berry DA, Hahn OM, Singh B, Hudis C, Winer EP: Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. *J Clin Oncol* 2010; 28(15s): Abst. TPS110.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS110](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS110)

Protocol(s): CALGB-40603

## ECOG

O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon RT, Cortes J, Zhou X, Phan S, Miller KD: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). *J Clin Oncol* 2010; 28(15s): Abst. 1005.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/1005](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1005)

Protocol(s): E2100

## NCCTG

Bueno Hume C, Moreno-Aspitia A, Hillman DW, Perez AT, Chen B, Jenkins RB, Dueck AC, Johnson DB, Carolla RL, Perez EA: Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. *J Clin Oncol* 2010; 28(15s): Abst. 565.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/565](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/565)

Protocol(s): N083E

Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA: N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. *J Clin Oncol* 2010; 28(15s): Abst. TPS129.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS129](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS129)

Protocol(s): N0733

Patel TA, Liu H, Hillman DW, Dueck AC, Ingle JN, Roy V, Hobday TJ, Northfelt DW, Perez EA: Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials. *J Clin Oncol* 2010; 28(15s): Abst. 1157.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/1157](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1157)

Protocol(s): Multiple Trials

## *NCIC Clinical Trials Group*

Tsvetkova EV, Chapman JW, Baetz TD, Burnell MJ, Gelmon KA, Pu N, O'Brien P, Shepherd LE, Goodwin PJ: Characterization of 25-OH vitamin D and factors associated with obesity in patients with high-risk breast cancer: NCIC CTG MA.21. *J Clin Oncol* 2010; 28(15s): Abst. 1578.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/1578](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1578)

Protocol(s): NCIC-MA.21

## *NSABP*

Krag DN, Anderson SJ, Julian TB, Brown A, Harlow SP, Costantino JP, Ashikaga T, Weaver D, Mamounas EP, Wolmark N: Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. *J Clin Oncol* 2010; 28(18s): Abst. LBA505.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA505](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA505)

Protocol(s): NSABP-B-32

Land SR, Christian N, Cronin WM, Wickerham D, Costantino JP, Ganz PA: Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT). *J Clin Oncol* 2010; 28(15s): Abst. 1524.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/1524](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1524)

Protocol(s): NSABP-P-1

Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, Wolmark N, Dowsett M, Forbes JF: Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. *J Clin Oncol* 2010; 28(15s): Abst. 509.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/509](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/509)

Protocol(s): NSABP-B-14, NSABP-B-20

## *SWOG*

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Hayes DF: Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. *J Clin Oncol* 2010; 28(15s): Abst. 511.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/511](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/511)

Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group

Protocol(s): INT-0100

Schott AF, Lew D, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Linden HM, Hortobagyi GN, Livingston RB: Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). *J Clin Oncol* 2010; 28(15s): Abst. 1006.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/1006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1006)

Protocol(s): S0430

## CNS Cancer

### COG

Ashley D: Systemic chemotherapy, second look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children > 8 months and < 3 years with nonmetastatic medulloblastoma: a Children's Oncology Group phase III study, follow up rep. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): POG-9233

Chintagumpala MM, Adesina AM, Morriss MC, Zhou T, Holmes E, Lau CC, Gajjar A: A pilot study using carboplatin, vincristine, and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study. J Clin Oncol 2010; 28(15s): Abst. 9539.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9539](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9539)

Protocol(s): ACNS0223

Chintagumpala MM, Adesina AM, Morriss MC, Zhou T, Holmes E, Lau CC, Gajjar A: A Children's Oncology Group (COG) pilot study using carboplatin, vincristine and temozolomide in children with progressive/symptomatic low-grade glioma. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): ACNS0223

Goldman S: A phase II trial of neoadjuvant chemotherapy +/- second-look surgery prior to radiotherapy for non-germinomatous germ cell tumors (NGGCT): Children's Oncology Group ACNS0122. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): ACNS0122

Jakacki RI: A phase II study of concurrent radiation and temozolomide (TMZ) followed by temozolomide and lomustine (CCNU) in the treatment of children with high grade glioma (HGG): results of COG ACNS0423. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): ACNS0423

Jakacki RI: Phase I study of vinblastine in combination with carboplatin for children with newly diagnosed and recurrent low-grade gliomas: Results of COG ADVL0515. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): ADVL0515

Packer RJ: Neuropsychological outcome in a study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma (MB): A Children's Oncology Group (COG) Study. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): A9961

Packer RJ: Secondary malignant neoplasms (SMNs) following "successful" treatment of nondisseminated medulloblastoma (MB): A 10-year follow-up of patients treated on a COG study. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.

<http://www.ispno2010.com/>

Protocol(s): A9961

## NCCTG

Galanis E, Jaeckle KA, Anderson S, Kaufmann TJ, Uhm JH, Giannini C, Kumar S, Northfelt DW, Flynn PJ, Buckner JC: NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. J Clin Oncol 2010; 28(15s): Abst. 2018.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/2018](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2018)

Protocol(s): N0776

Sarkaria JN, Galanis E, Gustafson MP, Dietz AB, Wu W, Brown PD, Uhm JH, Giannini C, Jaeckle KA, Buckner JC: Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D. J Clin Oncol 2010; 28(15s): Abst. 2016.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/2016](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2016)

Protocol(s): N027D

## RTOG

Chakravarti A, Wang M, Robins I, Guha A, Curran W, Brachman D, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M: Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond. J Clin Oncol 2010; 28(15s): Abst. 2062.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/2062](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2062)

Protocol(s): RTOG-0211

Gilbert M, Wang M, Aldape K, Sorensen A, Mikkelsen T, Bokstein F, Woo S, Chmura S, Choucair A, Mehta M: RTOG 0625: A randomized phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). International Conference on Brain Tumor Research and Therapy, Travemunde, Germany, May, 2010. Abst. XI-2.

[http://www.braintumor2010.de/braintumor2010\\_program.pdf](http://www.braintumor2010.de/braintumor2010_program.pdf)

Protocol(s): RTOG-0625

Lawrence Y, Wang M, Dicker A, Andrews D, Curran W, Michalski J, Souhami L, Yung W, Mehta M: Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. J Clin Oncol 2010; 28(15s): Abst. 2037.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/2037](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2037)

Protocol(s): RTOG-84-09, RTOG-90-06, RTOG-98-03, RTOG-97-10, RTOG-94-17, RTOG-BR-0013, RTOG-94-11, RTOG-93-02, RTOG-BR-0021, RTOG-95-13, RTOG-83-02, RTOG-96-02, RTOG-BR-0023, RTOG-98-06

## Gastrointestinal Cancer

### ACOSOG

Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP: Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. *J Clin Oncol* 2010; 28(15s): Abst. 10006.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/10006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10006)

Protocol(s): ACOSOG-Z9001

Garcia-Aguilar J, Shi Q, Thomas CR, Chan E, Cataldo P, Marcet J, Medich D, Pigazzi A, Oommen S, Posner M: Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial. *J Clin Oncol* 2010; 28(15s): Abst. 3510.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3510](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3510)

Protocol(s): ACOSOG-Z6041

### ACRIN

Fredericks N, Hartfeil D: ACRIN Implements New Strategies for Site and Participant Recruitment. Cancer Trials Accrual Symposium: Science and Solutions. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): ACRIN-6664

### CALGB

Enzinger PC, Burtness BA, Hollis DR, Niedzwiecki D, Ilson DH, Benson AB, Mayer RJ, Goldberg RM: CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. *J Clin Oncol* 2010; 28(15s): Abst. 4006.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4006)

Other Participant(s): ECOG

Protocol(s): CALGB-80403

### COG

Puumala SE, Feusner JH, Malogolowkin M, Krailo M, Ross JA, Spector LG: Infertility and hepatoblastoma: A report from the Children's Oncology Group (COG). American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 1828.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6039ff3d-549f-45ce-821e-9687d5d7b642&cKey=6aad66bf-4b49-4ff2-9d69-46f3fd8296a0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Protocol(s): AEPI04C1

Spector LG, Puumala SE, Tomlinson GE, Georgieff MK, Krailo M, Ross JA: Congenital abnormalities and hepatoblastoma: A report from the Children's Oncology Group (COG). American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 3774.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c631cc32-da11-432c-86fc-8dfdcfed870&cKey=f0fba763-41a8-4721-af08-3742fb1cc356&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Protocol(s): AEPI04C1

## ECOG

Berlin JD, Catalano P, Feng Y, Lowy AM, Blackstock AW, Philip PA, McWilliams RR, Abbruzzese JL, Benson AB: ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely-resected pancreatic adenocarcinoma. *J Clin Oncol* 2010; 28(15s): Abst. 4034.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4034](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4034)

Other Participant(s): CALGB, NCCTG, SWOG

Protocol(s): E2204

Gibson MK, Catalano P, Kleinberg LR, Staley CA, Montgomery EA, Song W, Mulcahy MF, Leichman LP, Benson AB: E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. *J Clin Oncol* 2010; 28(15s): Abst. 4064.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4064](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4064)

Protocol(s): E2205

Kim GP, Marsoni S, Monges G, Labianca R, Thibodeau SN, Hamilton SR, Kabat B, Sinicrope F, Gallinger S, Sargent DJ: Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. *Gastrointestinal Cancers Symposium*, Orlando, Florida, Jan, 2010. Abst. 342.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=2414](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2414)

Other Participant(s): CALGB, NCCTG, SWOG

Protocol(s): INT-0089, N994C

## NCCTG

Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S: Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. *J Clin Oncol* 2010; 28(18s): Abst. CRA3507.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/CRA3507](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA3507)

Protocol(s): N0147

Andre T, Shi Q, Yothers GA, Bot BM, Haller DG, Van Cutsem E, Cassidy J, Benedetti J, O'Connell M, Sargent DJ: Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)—Findings from the ACCENT dataset. *J Clin Oncol* 2010; 28(15s): Abst. 3616.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3616](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3616)

Other Participant(s): CALGB, ECOG, NSABP, SWOG

Protocol(s): INT-0089, N0441, NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06



Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne C, Seymour MT, De Gramont A, Goldberg RM, Sargent DJ: Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials. J Clin Oncol 2010; 28(15s): Abst. 3520.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3520](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3520)

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG  
Protocol(s): N9741

Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, Gill S, Kahlenberg MS, Nair S, Alberts SR: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; 28(15s): Abst. 3508.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3508](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3508)

Protocol(s): N0147

Grothey A, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Steen PD, Loui WS, Bot BM, Alberts SR, Reynolds JT: Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C. J Clin Oncol 2010; 28(15s): Abst. 3549.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3549](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3549)

Protocol(s): N054C

Kim GP, Marsoni S, Monges G, Allegra CJ, Thibodeau SN, Hamilton SR, Kabat B, Yothers GA, Gallinger S, Sargent DJ: Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC). J Clin Oncol 2010; 28(15s): Abst. 3518.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3518](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3518)

Other Participant(s): CALGB, ECOG, NSABP, SWOG  
Protocol(s): INT-0089, N994C, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04

Sargent D, Yothers G, Green E, Blanke CD, O'Connell MJ, Labianca R, Bleyer A, DeGramont A, Thomas D: Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset. J Clin Oncol 2010; 28(15s): Abst. 3523.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3523](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3523)

Other Participant(s): CALGB, ECOG, NSABP, SWOG  
Protocol(s): INT-0089, N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

Sinicrope FA, Foster NR, Sargent DJ, Gallinger S, Benatti P, Marsoni S, MongesG, Labianca R, O'Connell MJ, Allegra CJ: DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. J Clin Oncol 2010; 28(15s): Abst. 3519.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3519](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3519)

Other Participant(s): CALGB, ECOG, NSABP, SWOG  
Protocol(s): INT-0089, N994C, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04

Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Gallinger S, Moore MJ, Tu D: Evaluation of recurrence rate, time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 330.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=2351](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2351)

Protocol(s): N994C

Sinicrope FA, Foster NR, Sargent DJ, O'Connell MJ, Rankin C: Obesity is an independent prognostic variable in colon cancer survivors. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 904.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c6b7ae88-944b-4414-83af-25e4306e08fa&cKey=4addbc97-064c-4bcd-b958-c11ef9211bf2&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Protocol(s): N994C

## NSABP

Kunitake H, Zheng P, Yothers GA, Land SR, Petersen L, Fehrenbacher L, Giguere JK, Wickerham DL, Ko CY, Ganz PA: Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01. J Clin Oncol 2010; 28(15s): Abst. 9035.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9035](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9035)

Protocol(s): NSABP-LTS-01

McCahill LE, Yothers GA, Sharif S, Petrelli NJ, Lopa S, O'Connell MJ, Wolmark N: A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. J Clin Oncol 2010; 28(15s): Abst. 3527.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3527](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3527)

Protocol(s): NSABP-C-10

O'Connell MJ, Lavery IC, Gray RG, Quirke P, Kerr DJ, Lopatin M, Yothers GA, Lee M, Clark-Langone K, Wolmark N: Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. J Clin Oncol 2010; 28(15s): Abst. 3503.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3503](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3503)

Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

O'Connell MJ, Lavery IC, Gray RG, Quirke P, Kerr DJ, Lopatin M, Yothers GA, Lee M, Langone K, Wolmark N: Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 280.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=2334](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2334)

Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

Pogue-Geile KL, Yothers GA, Gavin P, Fumagalli D, Kim C, Colangelo LH, Geyer, CE Jr., O'Connell MJ, Wolmark N, Paik S: Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. J Clin Oncol 2010; 28(15s): Abst. 3516.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3516](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3516)

Protocol(s): NSABP-C-07

Yothers GA, O'Connell MJ, Colangelo L, Kuebler JP, Lopa S, Findlay MP, Seay TE, Atkins JN, Wolmark N: 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 401.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=2353](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2353)

Protocol(s): NSABP-C-07

## RTOG

Gunderson L, Moughan J, Ajani J, Pedersen J, Benson III A, Thomas Jr. C, Mayer R, Haddock M, Rich T, Willett C: Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in U.S. GI Intergroup RTOG 98-11 phase III trial. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 285.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=1297](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1297)

Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, SWOG

Protocol(s): RTOG-98-11

Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappen J, Haddock M, Rotman M, Parikh P, Willett C: RTOG 0529: A phase II study of dose-painted IMRT (DP-IMRT), 5-fluorouracil, and mitomycin-C for the reduction of acute morbidity in anal cancer. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 405.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=1606](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1606)

Protocol(s): RTOG-0529

## SWOG

Ladner RD, Ulrich CM, Rankin CJ, Danenberg KD, Danenberg PV, Smalley SR, Makar KW, Benedetti JK, Blanke CD, Lenz H: Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304). J Clin Oncol 2010; 28(15s): Abst. 3640.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3640](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3640)

Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG

Protocol(s): INT-0144

Philip PA, Goldman BH, Ramanathan RK, Lenz H, Lowy AM, Whitehead RP, Iqbal S, Chung VM, Benedetti JK, Blanke CD: SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2010; 28(15s): Abst. TPS223.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS223](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS223)

Protocol(s): S0727

Philip PA, Goldman BH, Ramanathan RK, Lenz H, Lowy AM, Whitehead RP, Iqbal S, Chung VM, Benedetti JK, Blanke CD: Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 233.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=2202](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2202)

Protocol(s): S0727

Thomas CR, Goldman BH, Benedetti JK, Lenz H, Beeker T, Abbruzzese JL, Blank C: Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy (TRT) as definitive treatment for locally advanced, unresectable esophageal cancer (EC): A SWOG (S0414) phase II trial. Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2010. Abst. 72.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=72&abstractID=1091](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1091)

Protocol(s): S0414

## Genitourinary Cancer

### CALGB

Halabi S, Rini BI, Stadler WM, Small EJ: Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010; 28(15s): Abst. 4525.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4525](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4525)

Protocol(s): CALGB-90206

Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP, Small EJ: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; 28(15s): Abst. LBA4511.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA4511](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA4511)

Other Participant(s): ECOG

Protocol(s): CALGB-90401

### ECOG

Chen Y, Kolesar J, Huang W, DiPaola RS, Pins MR, Carducci MA, Stein MN, Bubley GJ, Wilding G, Liu G: Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of kras and EGFR status on clinical outcome. J Clin Oncol 2010; 28(15s): Abst. 4668.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4668](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4668)

Protocol(s): E5803

Stein MN, Chen Y, Hudes GR, Carducci MA, Tan WW, DiPaola RS: ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(15s): Abst. 4556.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4556](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4556)

Protocol(s): E5805

### NCCTG

Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM, Schaefer PL, Krook JE, Bearden J, Loprinzi CL: Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB. J Clin Oncol 2010; 28(15s): Abst. 9139.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9139](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9139)

Protocol(s): N00CB

## *NCIC Clinical Trials Group*

Warde PR, Mason MD, Sydes MR, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Ding K, Parulekar W: Intergroup randomized phase III study of androgen deprivation therapy + radiation therapy in locally advanced prostate cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). *J Clin Oncol* 2010; 28(18s): Abst. CRA4504.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/CRA4504](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA4504)

Other Participant(s): CALGB, ECOG, SWOG

Protocol(s): T94-0110, CR-94-023

## *RTOG*

McGowan D, Hunt D, Jones C, Amin M, Leibenhaut M, Husian S, Rotman M, Souhami L, Sandler H, Shipley W: Effect of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: Initial results of RTOG 94-08. *Genitourinary Cancers Symposium, San Francisco, California, Mar, 2010*. Abst. 6.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=73&abstractID=30652](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30652)

Other Participant(s): OTHER

Protocol(s): RTOG-94-08

Sandler H, Hunt D, Sartor A, Gomella L, Hartford A, Zeitzer K, Rajan R, Kerlin K, Michalski J, Rosenthal S: A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. *J Clin Oncol* 2010; 28(15s): Abst. 4632.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4632](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4632)

Other Participant(s): OTHER

Protocol(s): RTOG-99-02

## *SWOG*

Goldkorn A, Xu T, Lu B, Williams A, Fink LM, Tangen CM, Twardowski P, Tai Y, Quinn DI, Cote R: Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. *J Clin Oncol* 2010; 28(15s): Abst. TPS342.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS342](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS342)

Protocol(s): S0421

Hussain M, Tangen CM, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, McLeod D, Crawford ED, Thompson IM: Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (pca): Better efficacy or stage migration? Data from SWOG: S9346 and 8894. *Genitourinary Cancers Symposium, San Francisco, California, Mar, 2010*. Abst. 30.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=73&abstractID=30449](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30449)

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER

Protocol(s): INT-0105, INT-0162

Lerner S, Stadler W, Groshen S, Cai J, Mitra A, Tuazon E, Skinner D, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R: Cell cycle regulatory protein alterations in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. *J of Urology* 2010; 183(4): Abst. 1715.

[http://www.jurology.com/article/S0022-5347\(10\)01818-5/fulltext](http://www.jurology.com/article/S0022-5347(10)01818-5/fulltext)

Protocol(s): SWOG-4B951

Marshall JR, Tangen CM, Sakr WA, Wood DP, Lippman SM, Jarrad D, Alberts DS, Berry DL, Crawford ED, Thompson IM: Southwest Oncology Group (SWOG) trial S9917: Randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia (HGPIN). *J of Urology* 2010; 183(4): Abst. (late breaking abstract).

Other Participant(s): CALGB, ECOG, OTHER

Protocol(s): S9917

Messing EM, Scosyrev E, Grossman HB, deVereWhite R, Trump DL, Natale RB, Tangen C, Crawford ED, Thompson IM: Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? Genitourinary Cancers Symposium, San Francisco, California, Mar, 2010. Abst. 274.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=73&abstractID=30750](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30750)

Other Participant(s): CALGB, ECOG

Protocol(s): INT-0080

Raghavan D, Tangen CM, Moinpour C, Gotay C, Albain KS, Louie S, Lenz H, Quinn DI, Hussain M, Thompson I: Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. *J Clin Oncol* 2010; 28(15s): Abst. 4569.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/4569](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4569)

Protocol(s): S0028

Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen C, Crawford ED, Thompson IM: Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? *J of Urology* 2010; 183(4): Abst. 1708.

[http://www.jurology.com/article/S0022-5347\(10\)01811-2/fulltext](http://www.jurology.com/article/S0022-5347(10)01811-2/fulltext)

Other Participant(s): CALGB, ECOG

Protocol(s): INT-0080

Thompson IM, Ely E, Tangen CM, Hussain MHA, Wood DP, Swanson GP, Quinn DI, Dorff TB, Dawson NA, Haas NB, Crawford ED: Southwest Oncology Group study 9921: Prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. *J of Urology* 2010; 183(4): Abst. (late breaking abstract).

Other Participant(s): CALGB, OTHER

Protocol(s): S9921

## Gynecologic Cancer

### GOG

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel R, Waggoner S, Schilder RJ, Alpaugh RK: Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 7.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf)

Protocol(s): GOG-0170I

Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, Monk BJ, Greer B, Boente MP, Liang SX: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. *J Clin Oncol* 2010; 28(18s): Abst. LBA1.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA1](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA1)

Protocol(s): GOG-0218

Chan J, Tian C, Kesterson J, Yang K, Kapp D, Monk B, Herzog T, Bell J: The pattern of CA-125 normalization during chemotherapy predicts for recurrence and survival in patients with high-risk early-stage ovarian cancer: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 36.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf)

Protocol(s): GOG-0157

Chan J, Tian C, Yang K, Kesterson J, Monk B, Herzog T, Bell J: The prognostic significance of pre-operative vs pre-chemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 116.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf)

Protocol(s): GOG-0157

Coleman RL, Brady W, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS: A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. *J Clin Oncol* 2010; 28(15s): Abst. 5010.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5010](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5010)

Protocol(s): GOG-0126R

Dewdney SB, Kizer N, Babb S, Rimmel B, Andaya A, Ali S, O'Malley D, Mannel R, Darcy K, DiSilvestro P, Lele S, Pearl M, Brinton L, Goodfellow P: Uterine serous carcinoma: increased familial risk for pancreatic cancer and other Lynch-associated malignancies: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 14.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVtb-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf)

Protocol(s): GOG-0120

Elgie WE, Killion J, Brehm P, Sill M, Brady WE, Fracasso P: Web-based management of phase I protocols in a cooperative group setting. Society for Clinical Trials, Baltimore, Maryland, May, 2010. Protocol(s): Multiple Trials

Gould N, Sill MW, Mannel RS, Fracasso P, Thaker PH, DiSilvestro P, Waggoner S, Yamada SD, Armstrong DK, Walker JL: A phase I trial of intravenous paclitaxel, intraperitoneal carboplatin, and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 34.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-9916

Hurteau JA, Brady MF, McGuire WP, Edmonds P, Darcy KM, Pearl ML, Ivanov I, Tewari K, Mannel RS, Zanotti K, Benbrook DM: A randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent only epithelial ovarian, fallopian tube or primary peritoneal carcinoma with an evaluation of serum vascular endothelial growth factor: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 2.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0198

Kuras A, Stonebraker B, Jelonek J, Elgie W, Brady M, Bialy S, Blessing J: Gynecologic Oncology Group (GOG): Quality control of electronically captured data. Society for Clinical Trials, Baltimore, Maryland, May, 2010.

Protocol(s): Multiple Trials

Lesnock J, Darcy K, Tian C, DeLoia J, Armstrong D, Birrer M, Gallion H, Krivak T: Association of single nucleotide polymorphisms in 5 loci of BRCA1 with clinical outcome in epithelial ovarian cancer patients treated with cisplatin and paclitaxel: A Gynecologic Oncology Group Study. *Gynecologic Oncology* 2010; 117(2): Abst. 5 (late breaking abstract).

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YRY9XG-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825810001745&\\_orig=search&\\_coverDate=05%2F31%2F2010&\\_sk=998829997&\\_view=c&\\_wchp=dGLbVIW-zSkWb&\\_md5=8d9c6ec94bd202ff95880693889406c9&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YRY9XG-3-1&_cdi=6814&_user=2391895&_pii=S0090825810001745&_orig=search&_coverDate=05%2F31%2F2010&_sk=998829997&_view=c&_wchp=dGLbVIW-zSkWb&_md5=8d9c6ec94bd202ff95880693889406c9&_ie=/sdarticle.pdf)

Protocol(s): GOG-0172

Lesnock J, Darcy K, Tian C, DeLoia J, Armstrong D, Birrer M, Gallion H, Krivak T: Association between reduced BRCA-1 expression and survival in patients with sporadic epithelial ovarian cancer treated with intraperitoneal versus intravenous cisplatin and paclitaxel: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 4.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0172



Liao SY, Rodgers WH, Kauderer J, Darcy KM, Carter R, Levine L, Spirtos NM, Susumu N, Fujiwara K, Walker JL, Hatae M, Stanbridge EJ: Carbonic anhydrase IX, p16 and human papillomavirus infection in endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia: A Gynecologic Oncology Group study. United States and Canadian Academy of Pathology, Washington, DC, Mar, 2010. Abst. 1130.

[http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L\\_1130](http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L_1130)

Protocol(s): GOG-0171

Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, De Geest K, Cohn DE, Monk BJ, Michael H: GOG 175: A randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m<sup>2</sup> Q 21 days x 3 courses plus low dose paclitaxel 40 mg/m<sup>2</sup>/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m<sup>2</sup> Q 21 days x 3 courses plus observation in patients with early stage ovarian cancer. Gynecologic Oncology 2010; 116(3): Abst. 1.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0175

Miller C, Hamilton C, Farley J, Chernofsky M, Krivak T, Miller A, Brady M, Staney M, Rose S, Maxwell G: The impact of disease distribution on survival in patients with advanced stage epithelial ovarian cancer cytoreduced to microscopic residual: A Gynecologic Oncology Group study. Gynecologic Oncology 2010; 116(3): Abst. 35.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Other Participant(s): ECOG, SWOG

Protocol(s): GOG-0114

Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, DeGeest K, Bonebrake A, Walker JL: Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 2010; 28(15s): Abst. 5046.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5046](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5046)

Protocol(s): GOG-0186F

Morgan M, Sill MW, Fujiwara K, Greer B, Rubin S, DeGeest K, Yamada SD, Waggoner S, Coleman R, Walker J, Mannel R: A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 2010; 116(3): Abst. 33.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-9917

Rubatt JM, Darcy KM, Tian CQ, Krivak TC, Muggia F, Dhir Rajiv, Armstrong DK, Niedernhofer LJ: The prognostic value of ERCC1 expression in patients with stage III epithelial ovarian cancer treated with cisplatin and paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology 2010; 116(3): Abst. 417.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0172

Stehman FB, Bialy SA, Seifert MM, Blessing JA: The impact of cooperative group publications on science and practice: A Gynecologic Oncology Group study. American Radium Society, Cancun, Mexico, May, 2010.

Protocol(s): Multiple Trials

Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull M, Monk B, Randall ME: The prognostic impact of number of positive lymph nodes and cervical stromal involvement among patients with advanced endometrial carcinoma treated with whole abdominal irradiation versus systemic chemotherapy: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2010; 116(3): Abst. 8.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0122

Usha L, Sill M, Darcy K, Benbrook D, Hurteau J, Michelin D, Mannel R, Hanjani P, De Geest K, Godwin A: A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. *Gynecologic Oncology* 2010; 116(3): Abst. 37.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YDSNXV-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825809010142&\\_orig=browse&\\_coverDate=03%2F31%2F2010&\\_sk=998839996.8998&\\_view=c&\\_wchp=dGLbVtb-zSkWA&\\_md5=1f4414cf3c0ca69aa057195403495c7d&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YDSNXV-3-1&_cdi=6814&_user=2391895&_pii=S0090825809010142&_orig=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&_view=c&_wchp=dGLbVtb-zSkWA&_md5=1f4414cf3c0ca69aa057195403495c7d&_ie=/sdarticle.pdf)

Protocol(s): GOG-0170J

von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Frasure HE, Armstrong DK, Wenzel LB: The association between quality of life and overall survival in ovarian survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study. *J Clin Oncol* 2010; 28(15s): Abst. 5075.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5075](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5075)

Protocol(s): GOG-0172

Walker J, Piedmonte M, Spirtos N, Eisenkop S, Spiegel G, Mannel R, Barakat R, Pearl M, Sharma S: Recurrence and survival after randomization to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer (Gynecologic Oncology Group LAP2). *Gynecologic Oncology* 2010; 117(2): Abst. 1.

[http://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B6WG6-4YRY9XG-3-1&\\_cdi=6814&\\_user=2391895&\\_pii=S0090825810001745&\\_orig=search&\\_coverDate=05%2F31%2F2010&\\_sk=998829997&\\_view=c&\\_wchp=dGLbVIW-zSkWb&\\_md5=8d9c6ec94bd202ff95880693889406c9&\\_ie=/sdarticle.pdf](http://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B6WG6-4YRY9XG-3-1&_cdi=6814&_user=2391895&_pii=S0090825810001745&_orig=search&_coverDate=05%2F31%2F2010&_sk=998829997&_view=c&_wchp=dGLbVIW-zSkWb&_md5=8d9c6ec94bd202ff95880693889406c9&_ie=/sdarticle.pdf)

Other Participant(s): OTHER

Protocol(s): GOG-LAP2

Zaino RJ, Brady WE, Todd W, Leslie K, Fischer E, Ball H: Histologic effects of short term progestin therapy on endometrioid adenocarcinoma. United States and Canadian Academy of Pathology, Washington, DC, Mar, 2010. Abst. 1211.

[http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L\\_1211](http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L_1211)

Protocol(s): GOG-0211

## NCCTG

Loprinzi CL, Balcueva EP, Liu H, Kottschade LA, Stella PJ, Carlson MD, Moore DF, Zon RT, Levitt R, Sloan JA: A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. *J Clin Oncol* 2010; 28(15s): Abst. 9024.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9024](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9024)

Protocol(s): N04CA

## NCIC Clinical Trials Group

Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA: Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression. *J Clin Oncol* 2010; 28(15s): Abst. 3090.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3090](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3090)

Protocol(s): NCIC-160

## RTOG

Schefter T, Moughan J, Kwon J, Stuhr K, Rotman M, Yaremo B, Small W, Gaffney D: RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. *J Clin Oncol* 2010; 28(15s): Abst. 5006.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5006)

Protocol(s): RTOG-0417

## Head and Neck Cancer

### ECOG

Egloff AM, Lee J, Seethala RR, Vaezi AE, Dacic S, Chiosea SI, Duensing AU, Langer CJ, Forastiere AA, Quon H, Burtness BA, Grandis JR: Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). *J Clin Oncol* 2010; 28(15s): Abst. 5537.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5537](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5537)

Protocol(s): E3303

Wanebo HJ, Ghebremichael M, Burtness BA, Spencer SA, Ridge JA, Forastiere AA: Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). *J Clin Oncol* 2010; 28(15s): Abst. 5513.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5513](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5513)

Protocol(s): E2303

## RTOG

Ang K, Zhang Q, Wheeler R, Rosenthal D, Nguyen-Tan F, Kim H, Lu C, Axelrod R, Silverman C, Weber R: A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. *J Clin Oncol* 2010; 28(15s): Abst. 5507.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5507](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5507)

Protocol(s): RTOG-0129

Chung C, Dignam J, Hammond M, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper J, Le Q, Ang K: Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). *J Clin Oncol* 2010; 28(15s): Abst. 5552.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5552](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5552)

Protocol(s): RTOG-90-03

Gillison M, Zhang Q, Ang K, Fu K, Hammond M, Jordan R, Trotti A, Spencer S, Rotman M, Chung C: Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. *J Clin Oncol* 2010; 28(15s): Abst. 5510.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5510](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5510)

Protocol(s): RTOG-90-03

Nguyen-Tan F, Pajak T, Wheeler R, Weber R, Rosenthal D, Lu C, Kim H, Axelrod R, Silverman C, Ang K: A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG0129): Report of efficacy and toxicity. Multidisciplinary Head and Neck Cancer Symposium, Chandler, Arizona, Feb, 2010. Abst. LB2.

Protocol(s): RTOG-0129

Sharma N, Harris J, Horwitz E, Langer C, Nicolaou N, Kies M, Curran Jr W, Wong S, Ang KK: Age, performance status and interval since prior radiation therapy predict for overall survival in re-irradiated head and neck cancer patients treated on RTOG 9911: Results of a recursive partitioning analysis. Multidisciplinary Head and Neck Cancer Symposium, Chandler, Arizona, Feb, 2010. Abst. PL7.

Protocol(s): RTOG-99-11

## SWOG

Bickel KE, Worden FP, Moon J, Kucuk O, Wheeler RH, Clark J, Wolf GT, Urba S: A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study. *J Clin Oncol* 2010; 28(15s): Abst. 5555.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5555](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5555)

Protocol(s): S0329

## Leukemia, Myelodysplasia, and Transplantation

### CALGB

Baer MR, George SL, Sanford BL, Stone RM, Marcucci G, Mayer RJ, Larson RA: Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. *J Clin Oncol* 2010; 28(15s): Abst. 6531.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/6531](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6531)

Protocol(s): CALGB-8923, CALGB-8525, CALGB-9720, CALGB-10201

Feusner JH, Gregory JJ, Moser BK, Hars V, Willman CL, Powell BL, Larson RA: Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. *J Clin Oncol* 2010; 28(15s): Abst. 9510.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9510](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9510)

Other Participant(s): COG, ECOG, NCIC Clinical Trials Group, SWOG

Protocol(s): C9710

Schwind S, Marcucci G, Holland KB, Mrózek K, Michael RD, Maharry K, Becker H, Whitman SP, Wu YZ, Carter TH, Powell BL, Caligiuri MA, Baer MR, Larson RA, Bloomfield CD: Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 2717.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3a98c08e-5100-427d-b077-f6c5984fe483&cKey=c8810c49-dae-4de8-8e66-da436a046dd0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Protocol(s): Multiple Trials

### COG

Druley TE, Giacalone J, Mitra RD: Using targeted pooled sample DNA sequencing to identify rare genetic variants associated with high-risk pediatric ALL. *Pediatr Blood Cancer* 2010; 54(6): Abst. 232.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): POG-9906

Gutierrez A, Dahlberg SE, Neuberg D, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Kutok JL, Winter SS, Larson RA, Borowitz M, Loh M, Silverman LB, Chin L, Hunger S, Sallan SE, Look AT: Absence of biallelic TCR-gamma deletions (ABGD) predicts induction failure in pediatric T-ALL. *Pediatr Blood Cancer* 2010; 54(6): Abst. 167.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): POG-9404

Heerema NA, Raetz E, Carroll AJ, Borowitz M, Devidas M, Larsen EC, Loh M, Mattano LA, Maloney K, Wood BL, Winick N, Hunger S, Carroll WL: Amplification of AML1 does not impact early event-free survival (EFS) or overall survival (OS) of children with acute lymphoblastic leukemia (ALL) treated with risk-directed chemotherapy: A report from the Children's Oncology Group (COG). *Pediatr Blood Cancer* 2010; 54(6): Abst. 181.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): AALL0232, AALL0331, AALL03B1

Hogan L, Mason C, Meyer J, Wang J, Tang Z, Brown SC, Morrison JL, Hunger S, Raetz E, Carroll WL: High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL). *J Clin Oncol* 2010; 28(15s): Abst. 9521.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9521](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9521)

Protocol(s): AALL03B1, AALL05B1, POG-9900

Hogan L, Meyer J, Wang J, Morrison D, Yang JJ, Hunger S, Willman CL, Raetz E, Bhojwani D, Carroll WL: Gene expression analysis reveals distinct signatures for early and late relapse in pediatric acute lymphoblastic leukemia (ALL). *Pediatr Blood Cancer* 2010; 54(6): Abst. 303B.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): AALL03B1, AALL05B1, POG-9900

Jurek AM, Greenland S, Spector LG, Roesler MA, Ross JA: Self-report versus medical record data in a study of infant leukemia: A report from the Children's Oncology Group. *Amer J Epidemiol* 2010; 171(11): Abst. 237.

[http://aje.oxfordjournals.org/cgi/reprint/171/suppl\\_11/S1](http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1)

Protocol(s): Multiple Trials

Loh M, Winter SS, Dunsmore KP, Raetz E, Borowitz M, Devidas M, Winick N, Carroll WL, Hunger SP, Wood BL: Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia have high levels of minimal residual disease at the end of induction--A Children's Oncology Group (COG) study. *Pediatr Blood Cancer* 2010; 54(6): Abst. 301A.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): AALL03B1

Meeske KA, Ji L, Butturini AM, Freyer DR, Gaynon PS, Ruccione K, Sposto R, Seibel N, Siegel S: Childhood cancer: Do females experience more acute toxicities than males? A report from the Children's Oncology Group. *International Nursing Conference on Children and Adolescent Cancer Survivorship*, Williamsburg, Virginia, Jun, 2010.

Protocol(s): CCG-1961

Meeske KA, Ji L, Butturini AM, Freyer DR, Gaynon PS, Ruccione K, Sposto R, Siegel S: Childhood cancer: Do females experience more acute toxicities than males? A report from the Children's Oncology Group. *International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer*, Williamsburg, Virginia, Jun, 2010.

<http://stjude.org/SJFile/Final%20Brochure.pdf>

Protocol(s): CCG-1961

Meeske KA, Ji L, Butturini AM, Freyer DR, Gaynon PS, Ruccione K, Sposto R, Siegel S: Childhood cancer: Do females experience more acute toxicities than males? A report from the Children's Oncology Group. *J Clin Oncol* 2010; 28(15s): Abst. 9515.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9515](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9515)

Protocol(s): CCG-1961

Myers K, Gerbing R, Alonzo T, Phillips C, Gamis A, Radloff GA, Perentesis JP, Davies SM: Pathway based evaluation of cytarabine pharmacogenetics in children with acute myeloid leukemia. *Pediatr Blood Cancer* 2010; 54(6): Abst. 173.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): CCG-2961

Raetz E, Devidas M, Carroll AJ, Heerema NA, Borowitz M, Wood BL, Gastier-Foster JM, Willman CL, Loh M, Larsen EC: Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. *J Clin Oncol* 2010; 28(15s): Abst. 9509.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9509](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9509)

Protocol(s): AALL0232

Schultz KR: Continuous dosing imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT with longer term follow up. *Pediatr Blood Cancer* 2010; 54(6): Abst. 300B.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): AALL0031

## Lung Cancer

### ACOSOG

Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, McKenna RJ, Jones DR, Inculet RI, Putnam JB: Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). *J Clin Oncol* 2010; 28(15s): Abst. 7021.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7021](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7021)

Protocol(s): ACOSOG-Z0030

### ACRIN

Duda C, Mahon I, Chen M-H, Snyder B, Barr R, Chiles C, Falk R, Fishman E, Gemmel D, Goldin J, Brown K, Munden R, Vydareny K, Aberle D: Impact of Targeted Recruitment of Minority Populations on the Distribution of Racial and Ethnic Participants in the National Lung Screening Trial. *Cancer Trials Accrual Symposium: Science and Solutions*. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/dqgfiles/ClinTrials/Track1.pdf>

Protocol(s): ACRIN-6654

Homick H, Hartfeil D, Fredericks N: American College of Radiology Imaging Network Works to Address Accrual Issues through use of a Screen Failure Log. *Cancer Trials Accrual Symposium: Science and Solutions*. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/dqgfiles/ClinTrials/Track3.pdf>

Protocol(s): ACRIN-6678

Lenz S, Black W: Recruitment for the ACRIN/6654 National Lung Screening Trial (NLST) at the Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, NH. *Cancer Trials Accrual Symposium: Science and Solutions*. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/dqgfiles/ClinTrials/Track2.pdf>

Protocol(s): ACRIN-6654

## CALGB

Capelletti M, Wang XF, Gu L, Graziano SL, Kratzke RA, Strauss GM, Maddaus M, Green MR, Vokes EE, Janne PA: Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. *J Clin Oncol* 2010; 28(15s): Abst. 7008.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7008](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7008)

Other Participant(s): NCCTG, RTOG

Protocol(s): CALGB-9633

Demmy TL, Gu L, Burkhalter JE, Toloza EM, D'Amico TA, Sutherland S, Wang XF, Archer L, Veit LJ, Kohman L: Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions. *J Clin Oncol* 2010; 28(15s): Abst. 9031.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9031](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9031)

Protocol(s): CALGB-30406

Dudek A, Pang H, Kratzke RA, Otterson GA, Vokes EE, Kindler HL: CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). *J Clin Oncol* 2010; 28(15s): Abst. 7037.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7037](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7037)

Protocol(s): CALGB-30601

Janne PA, Wang XF, Socinski MA, Crawford J, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke RA, Vokes EE, Miller VA: Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. *J Clin Oncol* 2010; 28(15s): Abst. 7503.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7503](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7503)

Protocol(s): CALGB-30406

Ready N, Dunphy F, Pang H, Heinze R, Crawford J, Vokes EE: Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. *J Clin Oncol* 2010; 28(15s): Abst. 7056.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7056](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7056)

Protocol(s): CALGB-30504

Salama AK, Pang H, Kratzke RA, Richards WG, Vokes EE, Salgia R: Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens. *J Clin Oncol* 2010; 28(15s): Abst. 10633.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/10633](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10633)

Protocol(s): CALGB-150607

## ECOG

Hamann HA, Lee J, Schiller JH, Horn L, Cleeland CS, Manola J, Wagner LI, Chang V, Fisch MJ: Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02). *J Clin Oncol* 2010; 28(15s): Abst. 9102.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9102](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9102)

Protocol(s): E2Z02



Karp DD, Lee SJ, Shaw Wright GL, Johnson DH, Johnston MR, Goodman GE, Clamon GH, Okawara GS, Marks R, Ruckdeschel JC: A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010; 28(18s): Abst. CRA7004.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/CRA7004](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA7004)

Other Participant(s): CALGB, NCCTG, NCIC Clinical Trials Group, RTOG, SWOG  
Protocol(s): E5597

Ramalingam SS, Lee J, Belani CP, Aisner S, Kolesar J, Howe CW, Velasco MR, Schiller JH: Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504). *J Clin Oncol* 2010; 28(15s): Abst. 7522.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7522](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7522)

Protocol(s): E1504

Zhang W, Lee J, Schiller JH, Carbone DP, Chung CH, Lenz H: Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. *J Clin Oncol* 2010; 28(15s): Abst. 7607.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7607](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7607)

Protocol(s): E2501

## NCCTG

Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H: Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. *J Clin Oncol* 2010; 28(15s): Abst. e16505.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/e16505](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e16505)

Protocol(s): N0723

Dy GK, Mandrekar SJ, Nelson GD, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA: A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010; 28(15s): Abst. 7603.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7603](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7603)

Protocol(s): N0528

Mandrekar SJ, Hillman SL, Allen-Ziegler K, Jatoi A, Jett JR, Schild SE, Adjei AA: Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. *J Clin Oncol* 2010; 28(15s): Abst. 7629.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7629](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7629)

Protocol(s): Multiple Trials

Qi Y, Dy GK, Nelson GD, Schild SE, Mandreka SJ, Adjei AA: Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. *J Clin Oncol* 2010; 28(15s): Abst. e18093.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/e18093](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e18093)

Protocol(s): Multiple Trials

Schild SE, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Foster NR, Adjei AA: N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15s): Abst. 7085.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7085](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7085)

Protocol(s): N0321

## *NCIC Clinical Trials Group*

Goss GD, Lorimer I, Tsao MS, O'Callaghan CJ, Ding K, Masters GA, Gandara DR, Jett JR, Edelman MJ, Shepherd FA: A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor, gefitinib in completely resected stage IB-IIIa non small cell lung cancer, NCIC CTG BR.19. J Clin Oncol 2010; 28(18s): Abst. LBA7005.

[http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA7005](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA7005)

Protocol(s): NCIC-BR.19

Twumasi-Ankrah P, Ding K, Seymour L, Shepherd FA, Tsao M-S: A sparse prognostic gene signature for stage IB and II patients with completely resected non-small cell lung cancer. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 1998.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=49b3a7a1-b6e0-43fe-b43c-e5742f53b9a6&cKey=3d8e63fc-b617-4a11-8bd3-1ef291e44ede>

Other Participant(s): CALGB, ECOG, SWOG

Protocol(s): JBR10

## *RTOG*

Suntharalingam M, Paulus R, Edelman M, Krasna MJ, Burrows W, Gore E, Yom S, Choy H: RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC. J Clin Oncol 2010; 28(15s): Abst. 7024.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/7024](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7024)

Protocol(s): RTOG 0229

## *SWOG*

Cassano PA, Arnold KB, Guertin K, Kristal AR, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Coltman CA, Klein E: Effect of vitamin E and selenium on incidence of physician-diagnosed COPD: The selenium and vitamin E cancer prevention trial (SELECT). Am J of Respiratory and Critical Care Medicine 2010; 181(1): Abst. A6765.

[http://ajrccm.atsjournals.org/cgi/reprint/181/1\\_MeetingAbstracts/A6765](http://ajrccm.atsjournals.org/cgi/reprint/181/1_MeetingAbstracts/A6765)

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

## Lymphoma and Plasma Cell Disorders

### CALGB

Kaplan LD, Jung S, Johnson JL, Linker CA, Byrd JC, Stock W, His ED, Cheson BD: A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. *J Clin Oncol* 2010; 28(15s): Abst. TPS306.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS306](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS306)

Protocol(s): CALGB-50403

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. *J Clin Oncol* 2010; 28(15s): Abst. 8017.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8017](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8017)

Other Participant(s): ECOG

Protocol(s): CALGB-100104

Morrison VA, Johnson JL, Jung S, Leonard JP, Cheson BD: A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. *J Clin Oncol* 2010; 28(15s): Abst. 8106.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8106](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8106)

Protocol(s): CALGB-50501

Smith SM, Bartlett N, Johnson JL, Lister J, Cashen AF, Jung S, Schöder H, Egan K, Cheson BD: Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. *J Clin Oncol* 2010; 28(15s): Abst. 8039.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8039](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8039)

Protocol(s): CALGB-50602

### COG

Cairo M, Lynch J, Harrison L, Perkins S, Shiramizu B, Gross TG, Sanger W, Goldman SC: Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report. *J Clin Oncol* 2010; 28(15s): Abst. 9536.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9536](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9536)

Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, Cairo M: A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children's Oncology Group report. *J Clin Oncol* 2010; 28(15s): Abst. 9572.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9572](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9572)

Protocol(s): ANHL01P1

Horton TM, Drachtman R, Chen L, Trippett T, de Alarcon PA, Chen AR, Guillerman RP, McCarten KM, Hogan SM, Schwartz CL: A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) study. *J Clin Oncol* 2010; 28(15s): Abst. 9537.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9537](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9537)

Protocol(s): AHOD0521

Kraveka JM, Weitzman S, Smith LM, Lynch J, Chang M, Kinney MC, Perkins S, Laver J, Gross TG, Weinstein H: Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group. *J Clin Oncol* 2010; 28(15s): Abst. 9511.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9511](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9511)

Protocol(s): ANHL0131

Shiramizu B, Goldman SC, Kusao I, Agsalda M, Lynch J, Harrison L, van de Ven C, Gross TG, Sanger W, Perkins S, Cairo M: Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report. *J Clin Oncol* 2010; 28(15s): Abst. 9527.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9527](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9527)

Protocol(s): ANHL01P1

## ECOG

Jacobus SJ, Wier SV, Ahmann G, Henderson K, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R: Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. *J Clin Oncol* 2010; 28(15s): Abst. 10546.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/10546](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10546)

Protocol(s): E4A03

## SWOG

Cook JR, Tubbs RR, Goldman B, Leblanc M, Rimsza L, Fisher R, Stiff R: Diffuse large B-cell lymphomas with high grade morphologic features and/or MYC translocations lack distinctive clinicopathologic features at presentation: A SWOG S9704 Study. United States and Canadian Academy of Pathology, Washington, DC, Mar, 2010. Abst. 1308.

[http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L\\_1308](http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L_1308)

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group

Protocol(s): S9704

Sanchorawala V, Bolejack V, Crowley J, Hoering A, Finn KT, Fennessey S, Seldin DC, Barlogie B: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial. *J Clin Oncol* 2010; 28(15s): Abst. 8022.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8022](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8022)

Protocol(s): S0115

## Melanoma/Skin Cancers

### ECOG

Flaherty KT, Lee S, Schuchter LM, Flaherty L, John JW, Leming PD, Kirkwood JM: Final results of E2603: A double-blinded, randomized phase III trial comparing carboplatin (C)/paclitaxel(P) with or without sorafenib (S) in metastatic melanoma. J Clin Oncol 2010; 28(15s): Abst. 8511.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8511](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8511)

Protocol(s): E2603

Kalinsky K, Lee S, Lawrence P, Kirkwood JM: A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). J Clin Oncol 2010; 28(15s): Abst. TPS312.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS312](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS312)

Protocol(s): E2607

Lawson DH, Lee S, Tarhini AA, Margolin KA, Ernstoff MS, Kirkwood JM: E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 2010; 28(15s): Abst. 8504.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8504](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8504)

Other Participant(s): CALGB, SWOG

Protocol(s): E4697

Slingluff CL, Lee S, Bullock KA, Olson W, Butterfield LH, Leming PD, Kirkwood JM: First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1602). J Clin Oncol 2010; 28(15s): Abst. 8508.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8508](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8508)

Protocol(s): E1602

### NCCTG

Dronca RS, Perez DG, Allred J, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic S: N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM). J Clin Oncol 2010; 28(15s): Abst. 8572.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8572](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8572)

Protocol(s): N0675

Markovic S, Suman V, Trieu VN, Liu X, Yeh W, Hwang L, Treece T, Motamed K, Pramanik P, Desai N: Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E. J Clin Oncol 2010; 28(15s): Abst. 8578.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8578](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8578)

Protocol(s): N057E

## SWOG

Margolin KA, Moon J, Flaherty L, Lao CD, Akerley III WL, Sosman JA, Kirkwood JM, Sondak VK: Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438. *J Clin Oncol* 2010; 28(15s): Abst. 8502.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8502](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8502)

Other Participant(s): ECOG

Protocol(s): S0438

Sondak VK, Tuthill R, Moon J, Thompson JA, Lao CD, Redmam BG, Flaherty LE: Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. *J Clin Oncol* 2010; 28(15s): Abst. 8517.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8517](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8517)

Other Participant(s): CALGB, COG, ECOG

Protocol(s): S0008

Sosman JA, Moon J, Liu P, Flaherty L, Atkins MB, Margolin KA, Kirkwood JM: Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. *J Clin Oncol* 2010; 28(15s): Abst. 8513.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/8513](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8513)

Other Participant(s): CALGB, COG, ECOG

Protocol(s): S0008

## Other Cancer

### ACRIN

Fredericks N, Hartfeil D: Project IMPACT: Integrating More Patient Advocates in Clinical Trials. Cancer Trials Accrual Symposium: Science and Solutions. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): Multiple Trials

### CALGB

Katz ML, Archer L, Peppercorn JM, Kereakoglow S, Collyar D, Burstein HJ, Schilsky RL, Partridge AH: The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB). *J Clin Oncol* 2010; 28(15s): Abst. 6148.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/6148](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6148)

Protocol(s): Multiple Trials

Kroetz DL, Baldwin RM, Owzar K, Jiang C, Zembutsu H, Kubo M, Nakamura Y, Shulman LN, Ratain MJ: Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. *J Clin Oncol* 2010; 28(15s): Abst. 3021.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3021](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3021)

Protocol(s): CALGB-40101

## COG

Attiyeh EF, Hogarty MD, Mosse YP, Diskin SJ, Hakonarson H, Asgharzadeh S, Sposto R, London WB, Gastier-Foster JM, Gerhard D, Smith MA, Zhang J, Khan J, Seeger RC, Maris JM: Genomic characterization and targeted resequencing of high-risk neuroblastoma (the neuroblastoma TARGET). Advances in Neuroblastoma Research, Stockholm, Sweden, Jun, 2010. Abst. POT2.

<http://www.anr2010.com/>

Protocol(s): Multiple Trials

Blanco JG, Sun C, Landier W, Chen L, Oeffinger KC, Hudson MM, Neglia JP, Ritchey AK, Relling MV, Bhatia S: Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study. J Clin Oncol 2010; 28(15s): Abst. 9512.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9512](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9512)

Protocol(s): ALTE03N1

Castel V, Matthay KK, Ambros PF, Monclair T, Pearson AD, Cohn S, London WB: Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) database. J Clin Oncol 2010; 28(15s): Abst. 9518.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9518](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9518)

Protocol(s): Multiple Trials

Cohn SL, Bhatia S, London WB, McGrady PW, Crotty CA, Sun C, Henderson TO: Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study. J Clin Oncol 2010; 28(15s): Abst. 9517.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9517](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9517)

Protocol(s): ANBL00B1

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan JJ, Seo S, Kim KM, Shusterman S, Gillies SD, Reisfeld R, Yang RK, Gadbow B, De Santes KB, London WB, Seeger RC, Maris JM, Sondel P: The potential role for genotypes of killer immunoglobulin-like receptors, their ligands, and Fc receptors to IgG on antitumor responses of neuroblastoma patients receiving the Hu14.18-IL2 (EMD 273063) immunocytokine: A Children's Oncology Group Report. Pediatr Blood Cancer 2010; 54(6): Abst. 304C.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): ANBL00B1

George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Diller L: Does tumor histology after induction therapy predict outcome in patients with high-risk neuroblastoma? Advances in Neuroblastoma Research, Stockholm, Sweden, Jun, 2010. Abst. POC10.

<http://www.anr2010.com/>

Protocol(s): Multiple Trials

Irwin MS, Naranjo A, Attiyeh EF, Seeger RC, Asgharzadeh S, Sposto R, Ji L, Yanik GA, Mosse YP, Maris JM, Park JR, London WB, Kreissman S, Hogarty MD: Is there an ultra-high-risk neuroblastoma group? Report from the Children's Oncology Group (COG) Clinical and Biological Risk Factors (CBRF) Task Force. *Advances in Neuroblastoma Research*, Stockholm, Sweden, Jun, 2010. Abst. POC13.

<http://www.anr2010.com/>

Protocol(s): Multiple Trials

Linabery AM, Slater M, Spector LG, Olshan A, Roesler MA, Ross JA: Feasibility of obtaining neonatal blood spots for pediatric cancer cases: A Children's Oncology Group (COG) study. *Amer J Epidemiol* 2010; 171(11): Abst. 232-S.

[http://aje.oxfordjournals.org/cgi/reprint/171/suppl\\_11/S1](http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1)

Protocol(s): Multiple Trials

London WB, Frantz CN, Campbell L, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L: Causal inference, a novel approach to disentangle the effects of off-protocol therapy from the primary effects of interest in COG protocol P9462: Topotecan vs. Topotecan+cyclophosphamide in relapsed neuroblastoma. *Advances in Neuroblastoma Research*, Stockholm, Sweden, Jun, 2010. Abst. SEL9.

<http://www.anr2010.com/>

Protocol(s): P9462

Mosse YP, Lipsitz EG, Maris JM, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Blaney SM: A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study. *J Clin Oncol* 2010; 28(15s): Abst. 9529.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9529](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9529)

Protocol(s): ADVL0812

Musselman JR, Jurek AM, Johnson KJ, Linabery AM, Robison L, Shu XO, Ross JA: Maternal dietary patterns during pregnancy and the risk of pediatric germ cell tumors (GCTs). *Amer J Epidemiol* 2010; 171(11): Abst. 225-S.

[http://aje.oxfordjournals.org/cgi/reprint/171/suppl\\_11/S1](http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1)

Protocol(s): AE22

Naranjo A, Parisi M, Shulkin BL, London WB, Matthay KK, Kreissman S, Yanik GA: Comparison of I-123 and I-131 mIBG scans in predicting survival in patients with stage 4 neuroblastoma. *Advances in Neuroblastoma Research*, Stockholm, Sweden, Jun, 2010. Abst. POC25.

<http://www.anr2010.com/>

Protocol(s): A3973

Oakley BE, Barnes YJ, Hendricks-Ferguson VL, Stegenga K, Robb SL, Haase JE: Strategies to support nurse participation in a cooperative group behavioral intervention study. *International Conference on Cancer Nursing*, Atlanta, Georgia, Mar, 2010. Abst. O-145.

[http://www.isncc.org/files/PDF/16th\\_ICCN\\_Abstract\\_Book.pdf](http://www.isncc.org/files/PDF/16th_ICCN_Abstract_Book.pdf)

Protocol(s): ANUR0631



Oakley BE, Hendricks-Ferguson VL, Burns DS, Roll LJ, Stegenga K, Docherty S, Robb SL, Haase JE: Recruiting Adolescents and Young Adults with Cancer into a Phase II Behavioral Intervention Study. International Conference on Cancer Nursing, Atlanta, Georgia, Mar, 2010. Abst. O-144.

[http://www.isncc.org/files/PDF/16th\\_ICCN\\_Abstract\\_Book.pdf](http://www.isncc.org/files/PDF/16th_ICCN_Abstract_Book.pdf)

Protocol(s): ANUR0631

Parisi M, Shulkin BL, Naranjo A, McGrady PW, London WB, Kreissman S, Yanik GA: Impact of MIBG scores on predicting survival in high risk neuroblastoma patients. J Nucl Med 2010; 51(2): Abst. 491.

[http://jnumedmtg.snmjournals.org/cgi/content/meeting\\_abstract/51/2\\_MeetingAbstracts/491](http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/51/2_MeetingAbstracts/491)

Protocol(s): A3973

Parisi M, Shulkin BL, Naranjo A, McGrady PW, London WB, Kreissman S, Yanik GA: MIBG Scores: A means of identifying an ultra-high risk group of patients. J Nucl Med 2010; 51(2): Abst. 490.

[http://jnumedmtg.snmjournals.org/cgi/content/meeting\\_abstract/51/2\\_MeetingAbstracts/490](http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/51/2_MeetingAbstracts/490)

Protocol(s): A3973

Park JR, London WB, Schmidt ML, Baker D, Kreissman S, Villablanca JG, Shimada H, Attiyeh EF, Hogarty MD, Maris JM, Matthay KK, Cohn SL: Outcome for stage 3 neuroblastoma: A report from the Children's Oncology Group. Advances in Neuroblastoma Research, Stockholm, Sweden, Jun, 2010. Abst. OR61.

<http://www.anr2010.com/>

Protocol(s): CCG-3891

Park JR, Hawkins DS, Ingle AM, Borinstein SC, Bender JG, Yamashiro D, Baruchel S, Chen AR, Adamson PC, Blaney SM: A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2010; 28(15s): Abst. 9530.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9530](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9530)

Protocol(s): ADVL0714

Pinto NR, Henderson TO, Bhatia S, London WB, McGrady PW, Crotty CA, Sun C, Cohn SL: Survival variability by race and ethnicity in neuroblastoma: A Children's Oncology Group (COG) Study. Advances in Neuroblastoma Research, Stockholm, Sweden, Jun, 2010. Abst. OR82.

<http://www.anr2010.com/>

Protocol(s): ANBL00B1

Robb SL, Burns DS, Docherty S, Haase JE: Ensuring treatment fidelity in a multi-site behavioral intervention study: Implementing NIH behavior change consortium recommendations in the SMART trial. International Conference on Music Therapy and Supportive Cancer Care, Windsor, Ontario, Canada, Mar, 2010.

<http://www.mtcancer.org/>

Protocol(s): ANUR0631

Warwick AB, Malempati S, Krailo M, Melemed AS, Adamson PC, Blaney SM: Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2010; 28(15s): Abst. 9535.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9535](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9535)

Protocol(s): ADVL0525

Yanik GA, Parisi M, Naranjo A, Matthay KK, London WB, McGrady PW, Kreissman S, Shulkin BL: MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. *J Clin Oncol* 2010; 28(15s): Abst. 9516.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9516](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9516)

Protocol(s): A3973

Yanik GA, Parisi M, Shulkin BL, Naranjo A, Kreissman S, London WB, Villablanca JG, McGrady PW, Matthay KK: Analyses of mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A Children's Oncology Group (A3973) report. *Advances in Neuroblastoma Research*, Stockholm, Sweden, Jun, 2010. Abst. PL30.

<http://www.anr2010.com/>

Protocol(s): A3973

## ECOG

Fisch MJ, Lee J, Chang VT, Wagner LI, Cella DF, Minasian LM, McCaskill-Stevens WJ, Weiss M, Smith ML, Cleeland C: A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). *J Clin Oncol* 2010; 28(15s): Abst. 9120.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9120](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9120)

Protocol(s): E2Z02

Tevaarwerk AJ, Lee J, Sesto MC, Buhr KA, Cleeland CS, Manola J, Wagner LI, Chang VT, Fisch M: Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study). *J Clin Oncol* 2010; 28(15s): Abst. 9118.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9118](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9118)

Protocol(s): E2Z02

## NCCTG

Atherton PJ, Burger KN, Loprinzi CL, Miller RC, Jatoi A, Sloan JA: Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). *J Clin Oncol* 2010; 28(15s): Abst. 9018.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9018](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9018)

Protocol(s): N0993

Barton DL, Moraska AR, Sood A, Sloan JA, Suh JJ, Griffin PC, Johnson DB, Ali AA, Silberstein PT, Loprinzi CL: Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7. *J Clin Oncol* 2010; 28(15s): Abst. 9004.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9004](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9004)

Protocol(s): N05C7

Reeves B, Dakhil SR, Sloan JA, Kamal A, Wolf SL, Burger KN, LeLindqwister N, Soori GS, Jaslowski AJ, Loprinzi CL: Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. *J Clin Oncol* 2010; 28(15s): Abst. 9135.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9135](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9135)

Protocol(s): NCCTG-N08C1

Sloan JA, Novotny PJ, Sargent DJ, Decker PA, Marks R, Nelson H: Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT). *J Clin Oncol* 2010; 28(15s): Abst. 6108.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/6108](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6108)

Protocol(s): NCCTG-89-20-52

Wolf SL, Qin R, Menon SP, Rowland KM, Kugler JW, Flynn PJ, Christian D, Satele D, Berenberg JL, Loprinzi CL: Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. *J Clin Oncol* 2010; 28(15s): Abst. 9017.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9017](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9017)

Protocol(s): N05C5

## *RTOG*

Bae K, Paulus R, Gramkowski M, Walters-Page L, McIlvaine J, Normolle D, Bezjak A: The implementation of a clinical trial using time-to-event continual reassessment method (TITE-CRM) in a cooperative group setting; Radiation Therapy Oncology Group (RTOG) 0813. Society for Clinical Trials, Baltimore, Maryland, May, 2010.

Protocol(s): RTOG-0813

Bruner J, Hartson-Stine S, James J, Heron D, Curran W, Watkins-Bruner D: Using cartographic mapping to assess and develop strategies to improve latino recruitment to Radiation Therapy Oncology Group clinical trials. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): Multiple Trials

Consoli S, James J, Pisansky T, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Kachnic L, Berk L, Watkins Bruner D: Process and funding barriers to symptom management trials conducted through NCI cooperative groups: The example of RTOG 0215. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): RTOG-0215

Reardon J, James J, Thomas T, Leistiko R, Neading J, Neimanis D, Stern J, Consoli S, Hanish L, Watkins Bruner D: Identification of patient level barriers and facilitators to RTOG clinical trials recruitment. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): Multiple Trials

Ulrich C, James J, Walker E, Hartson-Stine S, Gore E, Prestidge B, Michalski J, Gwede C, Waite T, Watkins-Bruner D: What is "adequate knowledge" in communicating clinical trials? Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Protocol(s): Multiple Trials

## SWOG

Anderson KB, Cook ED, Hamilton SJ, Minasian LM, Hermos JA, Probstfield JL: Infrastructure for successful recruitment when conducting a multi-site clinical trial: the SELECT experience. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

Cook E, Arnold K, Hermos J, McCaskill-Stevens W, Moody-Thomas S, Probstfield J, Hamilton SJ, Campbell R, Anderson K, Minasian L: Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

Cook E, Arnold K, Hermos J, McCaskill-Stevens W, Moody-Thomas S, Probstfield J, Hamilton SJ, Campbell R, Anderson K, Minasian L: Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. Society for Clinical Trials, Baltimore, Maryland, May, 2010.

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

Hamilton SJ, Cook ED, Anderson KB, Sheats JQ: The role of a community based organization in a large prevention trial. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

Harris-Talley JM, Arney D, Anderson K, Hartline JA: Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials. Society for Clinical Trials, Baltimore, Maryland, May, 2010.

Other Participant(s): CALGB, ECOG, NCCTG, RTOG

Protocol(s): S0000

## Sarcoma/Bone and Soft Tissue Cancers

### COG

Arndt CA, Koshkina NV, Inwards C, Hawkins D, Krailo M, Villaluna D, Anderson P, Goorin A, Blakely M, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES: Inhaled GM-CSF for First Pulmonary Recurrence of Osteosarcoma: Report from the Children's Oncology Group. *Pediatr Blood Cancer* 2010; 54(6): Abst. 283.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): AOST0221

Leavey P, Bender JG, Mascarenhas L, Granowetter L, Anderson ME, Krailo M, Gorlick RG, Marina NM: Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study. *J Clin Oncol* 2010; 28(15s): Abst. 9552.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9552](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9552)

Protocol(s): AEWS0521

Malempati S, Rodeberg D, Donaldson S, Hawkins D, Arndt CA: Rhabdomyosarcoma in infants less than one year of age: Results from the Children's Oncology Group. *Pediatr Blood Cancer* 2010; 54(6): Abst. 282.

<http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART>

Protocol(s): INT-0117, INT-0118, D9602, INT-0119

Rodeberg D, Wharam MD, Lyden E, Stoner JA, Brown KL, Wolden SL, Paidas CN, Donaldson S, Hawkins D, Spunt SL, Arndt CA: Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG). *J Clin Oncol* 2010; 28(15s): Abst. 9504.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9504](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9504)

Protocol(s): D9803

Scannell CA, Abdueva D, Ji L, von Levetzow C, Sposto R, Triche T, Lawlor B: High expression of the stem cell marker LGR5 is associated with a poor clinical outcome in patients with Ewing's sarcoma. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 4640.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=937e2d4b-4992-420f-833d-358b59b869c0&cKey=2db70d99-39aa-43c7-a84e-0c6bef7b2bd1&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Protocol(s): AEWS0031

Weigel BJ, Lyden E, Anderson J, Galster AE, Arndt CA, Michalski J, Hawkins D, Meyer WH: Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). *J Clin Oncol* 2010; 28(15s): Abst. 9503.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9503](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9503)

Protocol(s): ARST0431

## NCI/CTEP Abstracts & Activities

### Abstracts with DCTD and DCP Investigators

Anderson KB, Cook ED, Hamilton SJ, Minasian LM, Hermos JA, Probstfield JL: Infrastructure for successful recruitment when conducting a multi-site clinical trial: the SELECT experience. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

Attiyeh EF, Hogarty MD, Mosse YP, Diskin SJ, Hakonarson H, Asgharzadeh S, Sposto R, London WB, Gastier-Foster JM, Gerhard D, Smith MA, Zhang J, Khan J, Seeger RC, Maris JM: Genomic characterization and targeted resequencing of high-risk neuroblastoma (the neuroblastoma TARGET). Advances in Neuroblastoma Research, Stockholm, Sweden, Jun, 2010. Abst. POT2.

<http://www.anr2010.com/>

Cassano PA, Arnold KB, Guertin K, Kristal AR, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Coltman CA, Klein E: Effect of vitamin e and selenium on incidence of physician-diagnosed COPD: The selenium and vitamin e cancer prevention trial (SELECT). Am J of Respiratory and Critical Care Medicine 2010; 181(1): Abst. A6765.

[http://ajrccm.atsjournals.org/cgi/reprint/181/1\\_MeetingAbstracts/A6765](http://ajrccm.atsjournals.org/cgi/reprint/181/1_MeetingAbstracts/A6765)

Cook E, Arnold K, Hermos J, McCaskill-Stevens W, Moody-Thomas S, Probstfield J, Hamilton SJ, Campbell R, Anderson K, Minasian L: Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. Cancer Trial Accrual Symposium, Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H: Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. J Clin Oncol 2010; 28(15s): Abst. e16505.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/e16505](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e16505)

Fisch MJ, Lee J, Chang VT, Wagner LI, Cella DF, Minasian LM, McCaskill-Stevens WJ, Weiss M, Smith ML, Cleeland C: A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). J Clin Oncol 2010; 28(15s): Abst. 9120.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/9120](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9120)

Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA: N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. J Clin Oncol 2010; 28(15s): Abst. TPS129.

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/TPS129](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS129)

Houghton PJ, Maris, JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Smith MA: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of BMS-754807IGF-1 receptor inhibitor. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 5265.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c278f6aa-8185-4c9c-a957-ea12be9a7e18&cKey=a183115e-b965-4002-a19f-9d22c0ab1375&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

Meeske KA, Ji L, Butturini AM, Freyer DR, Gaynon PS, Ruccione K, Sposto R, Seibel N, Siegel S: Childhood cancer: Do females experience more acute toxicities than males? A report from the Children's Oncology Group. International Nursing Conference on Children and Adolescent Cancer Survivorship, Williamsburg, Virginia, Jun, 2010.

Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kold EA, Kang M, Reynolds CP, Morton CL, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965. American Association of Cancer Research (AACR), Washington, DC, Apr, 2010. Abst. 5266.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c278f6aa-8185-4c9c-a957-ea12be9a7e18&cKey=a183115e-b965-4002-a19f-9d22c0ab1375&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d>

## DCTD and DCP Activities

### Scientific

Denicoff AM (DCTD/CTEP) and McCaskill-Stevens WJ (DCP/COPTRG): NCI Co-Chairs; Grubbs SS and Meropol NJ: ASCO Co-Chairs for NCI-ASCO Cancer Trials Accrual Symposium: Science and Solutions. Bethesda, Maryland, Apr, 2010.

<http://university.asco.org/CT2010>

Seibel NL (DCTD/CTEP): Organizer for NCI-COG workshop: Osteonecrosis in Pediatric and Adolescent Acute Lymphoblastic Leukemia (ALL): Insights into the Etiology of this Emerging Toxicity. Rockville, Maryland, Jan, 2010.

**Disclaimer:** References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.